Disease · MONDO_0005411
gallbladder cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. gallbladder cancer. Diseases, record MONDO_0005411. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005411
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cancer of gall bladder, gall bladder cancer, malignant gall bladder neoplasm, malignant gallbladder neoplasm, malignant gallbladder tumor, malignant gallbladder tumour, malignant neoplasm of gall bladder, malignant neoplasm of gallbladder, malignant neoplasm of the gallbladder, malignant tumor of gallbladder, malignant tumor of the gallbladder, malignant tumour of gallbladder, malignant tumour of the gallbladder
- Open Targets
Drugs65
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 38 | 38 | 38 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 24 | 24 | 24 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 14 | 14 | 7 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| TRASTUZUMAB | CHEMBL1201585 | Antibody | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| FOSGEMCITABINE PALABENAMIDE | CHEMBL3126004 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 14 | 14 | 14 | Drugs and targets |
| DURVALUMAB | CHEMBL3301587 | Antibody | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 65
See all 65 drugsTargets85
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 7 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 6 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 5 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 2/3 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| ERBB2 | Epidermal growth factor receptor | 5 | Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 3 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 5 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| TUBA1A | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 5 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
1 to 10 of 85
See all 85 targetsTrials83
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04163900 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | Phase 3 | 773 | 2023-05-24 | Biliary Tract Cancer | CISPLATIN, FOSGEMCITABINE PALABENAMIDE, GEMCITABINE | Its record names the disease | ClinicalTrials.gov |
| NCT03733990 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Phase 1/2 | 216 | 2025-04-02 | Cancer | BEXMARILIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00753675 | Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer | Phase 2 | 174 | 2013-11-28 | Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma | GEMCITABINE, VANDETANIB | Its record names the disease | ClinicalTrials.gov |
| NCT04466891 | A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers | Phase 2 | 87 | 2024-08-21 | HER2-amplified Biliary Tract Cancers | ZANIDATAMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03201458 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | Phase 2 | 86 | 2023-07-11 | Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Cholangiocarcinoma | ATEZOLIZUMAB, COBIMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02392637 | Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | Phase 2 | 62 | 2022-02-02 | Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma | CISPLATIN, GEMCITABINE HYDROCHLORIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT02520141 | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery | Phase 2 | 61 | 2023-06-15 | Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Stage III Gallbladder Cancer AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma | RAMUCIRUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00033540 | S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma | Phase 2 | 57 | 2012-08-28 | Extrahepatic Bile Duct Cancer, Gallbladder Cancer | CAPECITABINE, GEMCITABINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery | Phase 2 | 53 | 2017-08-10 | Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Childhood Liver Cancer, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Stage II Gallbladder Cancer, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Childhood Hepatocellular Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma | CAPECITABINE, FLUOROURACIL, LEUCOVORIN CALCIUM, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03790111 | A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer | Phase 2 | 53 | 2023-04-19 | Biliary Tract Cancer (BTC) | CISPLATIN, GEMCITABINE, TELOTRISTAT ETHYL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 83
See all 83 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: deaths from any cause | 188 of 388 | 135 of 385 | 773 | NCT04163900 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: serious adverse events | 175 of 383 | 126 of 378 | 761 | NCT04163900 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: Objective Response Rate (ORR) | 53 of 284 | 34 of 275 | 559 | NCT04163900 | Trial comparisons |
| Cohort I vs Cohort II: ORR by Investigator Assessment | 34 of 80 | 0 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR) | 33 of 80 | 0 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: DCR by Investigator Assessment | 54 of 80 | 1 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: Incidence of Laboratory Abnormalities | 37 of 80 | 7 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: deaths from any cause | 60 of 80 | 6 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: Disease Control Rate (DCR) by ICR | 55 of 80 | 3 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: serious adverse events | 43 of 80 | 3 of 7 | 87 | NCT04466891 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials54
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005411
GET https://conductscience.org/api/diseases/v1/MONDO_0005411/drugs?page=2